Predictive Model for Mortality in Older People With Critical Illness (VITA)

Development of a Predictive Model for Mortality in Patients Aged 75 or Older With Critical Illness

The present study aims to develop a predictive model to identify elderly patients with the highest likelihood of mortality upon admission to an intensive care unit.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Barcelona, Spain
        • Not yet recruiting
        • Hospital Del Mar
        • Contact:
        • Principal Investigator:
          • Ana Zapatero
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital Clinic
        • Principal Investigator:
          • Pedro Castro
        • Contact:
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital de la Santa Creu i Sant Pau
        • Contact:
        • Principal Investigator:
          • Carles Subirà
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital General de Catalunya
        • Contact:
        • Principal Investigator:
          • María Dolores Bosque
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital de Barcelona
        • Contact:
        • Principal Investigator:
          • Karla Núñez
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital de Mataró
        • Contact:
        • Principal Investigator:
          • Estel Güell
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital de Terrassa
        • Contact:
        • Principal Investigator:
          • Manuel Buitrago
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital Dexeus Barcelona
        • Contact:
        • Principal Investigator:
          • Elida Amestoy
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital General de Granollers
        • Contact:
        • Principal Investigator:
          • Zaira Chova
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital Sagrat Cor
        • Contact:
        • Principal Investigator:
          • Omar Correa
      • Girona, Spain
        • Not yet recruiting
        • Hospital Universitari Dr. Josep Trueta
        • Contact:
        • Principal Investigator:
          • Jordi Parisi
      • Girona, Spain
        • Not yet recruiting
        • Hospital Santa Caterina
        • Contact:
        • Principal Investigator:
          • Malena Tejada
      • Girona, Spain
        • Not yet recruiting
        • Clinica Girona
        • Contact:
        • Principal Investigator:
          • Mariano Rinaudo
    • Barcelona
      • Badalona, Barcelona, Spain, 08916
        • Recruiting
        • Hospital German Trias i Pujol
        • Contact:
        • Principal Investigator:
          • Regina Roig, MD
      • Sant Pere de Ribes, Barcelona, Spain, 08810
        • Not yet recruiting
        • Consorci Sanitari Alt Penedès-Garraf
        • Contact:
        • Contact:
        • Principal Investigator:
          • Fernando Gerber, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients admitted to a Intensive Care Unit

Description

Inclusion Criteria:

  • Men and women aged 75 or older.
  • Admission to an ICU from the Emergency Department.
  • Availability of or possibility to contact a participant's informant.
  • Informed consent for participation in the study, either by the participant or a valid legal representative.

Exclusion Criteria:

Participants meeting any of the following exclusion criteria will not be included in the study:

  • Patients transferred to the Emergency Department from a hospital ward.
  • Patients who die within the first 24 hours of ICU admission.
  • Patients admitted to Step-Down Units.
  • Patients requiring ICU admission for any of the following reasons:

Orotracheal intubation or advanced cardiopulmonary resuscitation performed prior to arrival at the Emergency Department.

AV block awaiting pacemaker implantation. Activation of the STEMI or Stroke care pathway. Post-cardiac catheterization for acute coronary syndrome.

  • Participation in another clinical study involving an intervention, procedure, or visit schedule that is incompatible with the present study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mortality
Time Frame: Day 90
mortality on day 90 from admission to Intensive Care Unit
Day 90

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 20, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

December 5, 2024

First Submitted That Met QC Criteria

December 10, 2024

First Posted (Actual)

December 11, 2024

Study Record Updates

Last Update Posted (Actual)

December 2, 2025

Last Update Submitted That Met QC Criteria

December 1, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

IPD Sharing Time Frame

After publication of main results of the study.

IPD Sharing Access Criteria

IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness

Clinical Trials on laboratory biomarker analysis

Subscribe